Trius Therapeutics Inc. (TSRX) posted fourth-quarter net loss of $14.2 million or $0.36 per share, wider than $12.5 million or $0.44 per share in the comparable quarter last year.
On average, ten analysts polled by Thomson Reuters expected the company to report a loss of $0.47 per share. Analysts' estimates typically exclude special items.
Total revenues for the quarter were $5.16 million, compared with $5.00 million in the prior year quarter, while nine analysts had consensus revenue estimate of $4.60 million for the quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.